Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
US Department of Justice
Merck
UBS
Federal Trade Commission
Moodys
Harvard Business School
Argus Health

Generated: November 19, 2018

DrugPatentWatch Database Preview

Sanofi Company Profile

« Back to Dashboard

What is the competitive landscape for SANOFI, and what generic alternatives to SANOFI drugs are available?

SANOFI has one hundred and fifty approved drugs.

There are seventy-three US patents protecting SANOFI drugs.

Drugs and US Patents for Sanofi

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us KERLONE betaxolol hydrochloride TABLET;ORAL 019507-002 Oct 27, 1989 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us AUBAGIO teriflunomide TABLET;ORAL 202992-001 Sep 12, 2012 AB RX Yes No 6,794,410 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes 9,440,029 ➤ Try a Free Trial Y ➤ Try a Free Trial
Sanofi Aventis Us NICODERM CQ nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020165-004 Aug 2, 1996 OTC Yes Yes 8,999,379 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi-aventis Us ADMELOG SOLOSTAR insulin lispro SOLUTION;IV (INFUSION), SUBCUTANEOUS 209196-002 Dec 11, 2017 RX Yes No 8,992,486 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Sanofi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us AVALIDE hydrochlorothiazide; irbesartan TABLET;ORAL 020758-003 Aug 31, 1998 5,270,317*PED ➤ Try a Free Trial
Sanofi Aventis Us NICODERM CQ nicotine FILM, EXTENDED RELEASE;TRANSDERMAL 020165-006 Aug 2, 1996 5,462,745 ➤ Try a Free Trial
Sanofi Aventis Us ALLEGRA ALLERGY fexofenadine hydrochloride TABLET;ORAL 020872-010 Jan 24, 2011 7,135,571*PED ➤ Try a Free Trial
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 6,372,780 ➤ Try a Free Trial
Sanofi Aventis Us PLAVIX clopidogrel bisulfate TABLET;ORAL 020839-001 Nov 17, 1997 4,847,265*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SANOFI drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 75 mg, 150 mg and 300 mg ➤ Subscribe 2004-05-25
➤ Subscribe Tablets 800 mg ➤ Subscribe 2008-12-04
➤ Subscribe Tablets 300 mg ➤ Subscribe 2009-03-04
➤ Subscribe Oral Suspension 30 mg/5 mL ➤ Subscribe 2010-01-25
➤ Subscribe Oral Solution 0.5 mg/mL ➤ Subscribe 2009-01-14
➤ Subscribe Injection 40 mg/mL, 0.5 mL and 2 mL vials ➤ Subscribe 2009-06-30
➤ Subscribe Injection 5 mg/mL, 10 mL and 20 mL vials ➤ Subscribe 2007-02-09
➤ Subscribe Injection 200 mg/40 mL ➤ Subscribe 2007-07-16
➤ Subscribe Extended-release Tablets 6.25 mg ➤ Subscribe 2006-02-24
➤ Subscribe Tablets 7 mg and 14 mg ➤ Subscribe 2016-09-12
➤ Subscribe Injection 2 mcg/mL, 2 mL ampules ➤ Subscribe 2007-10-15
➤ Subscribe Tablets 300 mg/25 mg ➤ Subscribe 2006-06-06
➤ Subscribe Injection 2 mcg/mL, 1 mL in 2 mL vial ➤ Subscribe 2011-12-28
➤ Subscribe Tablets 400 mg ➤ Subscribe 2013-07-01
➤ Subscribe Powder for Oral Suspension 0.8 g/packet and 2.4 g/packet ➤ Subscribe 2009-12-30
➤ Subscribe Tablets 150 mg ➤ Subscribe 2007-10-30
➤ Subscribe Transdermal System 7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs ➤ Subscribe 2014-05-30
➤ Subscribe Tablets 5 mg ➤ Subscribe 2007-12-17
➤ Subscribe Injection 100 mg/mL, 3 mL vials ➤ Subscribe 2006-12-07
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2007-02-09
➤ Subscribe Injection 5 mg/mL, 40 mL vial ➤ Subscribe 2011-03-23
➤ Subscribe Extended-release Tablets 12.5 mg ➤ Subscribe 2006-01-19
➤ Subscribe Capsules 0.5 mcg and 2.5 mcg ➤ Subscribe 2009-03-25
➤ Subscribe Tablets 150 mg/12.5 mg and 300 mg/12.5 mg ➤ Subscribe 2004-11-10
➤ Subscribe Capsules 1 mcg ➤ Subscribe 2010-02-12
Premature patent expirations for SANOFI

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Supplementary Protection Certificates for Sanofi Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2004005 Lithuania ➤ Try a Free Trial PRODUCT NAME: INSULIN DETEMIR
1 5019-2013 Slovakia ➤ Try a Free Trial FIRST REGISTRATION NO/DATE: EU/1/11/676/001 20110317
172 Luxembourg ➤ Try a Free Trial PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
60026 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULINUM LISPRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/007/001 - EU/1/96/007/003 19960430
C0009 Belgium ➤ Try a Free Trial PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chubb
Cerilliant
US Department of Justice
Daiichi Sankyo
Healthtrust
US Army
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.